Colorectal cancer metastatic towards the liver: making the unresectable resectable


Alliance for Clinical Trials in OncologyProbably the most common tumor types that surgical oncologists focusing on hepatobiliary and pancreatic neoplasms see in clinical practice is colorectal cancer liver metastases. This truth is unsurprising, considering that colorectal cancer may be the third-most common cancer within the U.S. Roughly one out of 20 Americans will build up colorectal cancer within their lifetime.1 Resection of hepatic metastases supplies a five-year rate of survival of 30 % to 50 % and is the treatment preferred by patients with resectable disease.2,3 Regrettably, most sufferers aren’t candidates for metastasectomy sometimes of diagnosis.4-6

Consider, for instance, a 51-year-old lady with colorectal liver metastases involving both lobes from the liver with a minimum of 12 lesions particularly described within the magnetic resonance imaging report, that also incorporated the word “innumerable hepatic metastases.” Within the 1990s, this ailment could have been considered unresectable, and also the patient might have received systemic chemotherapy having a median survival of 15 several weeks.7 However, much has altered since that time in treating metastatic colorectal cancer, that has brought to greatly improved survival, specifically for patients with liver-only disease. These new approaches have elevated the function of surgeons in the treating of these patients.

Advances in chemotherapy

The most crucial development continues to be the development of more efficient chemotherapeutic agents for stage IV colorectal cancer. Drugs for example Oxaliplatin and Irinotecan, when coupled with 5-Fluorouracil/Leucovorin, have created response rates within the 50 % range and median survivals as much as 20 several weeks.8

Hepatic resection

Ale chemotherapy to lower the dimensions and quantity of tumor masses has brought to downstaging of liver metastases, that have been initially considered unresectable, to resectable. Adam and colleagues shown that systemic chemotherapy downstaged 12.five percent of patients with inoperable disease, enabling these to undergo hepatic resection. The 5-year overall survival of the group was 33 percent.9 A current paper from China reported that utilizing an even newer systemic therapy regimen that contains cetuximab, a biologic agent, plus chemotherapy to downstage unresectable liver metastases, a quarter of patients could undergo surgery having a median survival of 35 several weeks.10 These studies show patients with advanced colorectal liver metastases still are able to endure resection of hepatic metastases when they respond well to systemic therapy.

Numerous studies needed

Questions remain concerning the timing of systemic therapies and also the role of surgery that should be addressed in numerous studies. An editorial within the Journal of Clinical Oncology highlighted some key issues, for example whether patients with resectable disease should undergo neoadjuvant chemotherapy and whether these patients could be stratified into good-risk and poor-risk groups.11 Also elevated were queries about the very best preoperative systemic therapy regimen for patients with unresectable hepatic metastases.11

Although certain patients show some reaction to neoadjuvant systemic therapy, they have extensive bilateral disease which may be considered unresectable using traditional surgical approaches. In these instances, patient selection and enhancements in surgical technique have permitted surgeons to get rid of all disease using two-stage hepatic resections coupled with portal vein embolization. Vauthey and colleagues in the College of Texas MD Anderson Cancer Center, Houston, reported their outcomes by using this approach in 65 patients. During these patients who’d taken care of immediately systemic therapy, a restricted resection of disease within the left liver was performed, adopted by right portal vein embolization, after which, at a second operation, a long right hepatectomy. Roughly 30 % of patients who’d the very first surgery dropped out because of tumor progression, but individuals patients who could undergo the 2nd operation were built with a five-year overall rate of survival of 51 percent.12 The individual described earlier could undergo this method and also have all hepatic metastases resected. Figures 1A–D demonstrate computed tomography pictures of her disease at various stages of treatment.

Figures 1A, 1B, 1C, 1D

Because less than 10 % of patients with advanced colorectal cancer could be candidates with this approach, a multicenter trial could be needed to reply to queries about which patients are the most useful candidates. Just how much reaction to systemic treatments are needed, as based on radiographic imaging or biochemical markers? What’s the optimal timing from the liver operations and portal vein embolization? In the event of synchronous metastatic disease, what’s the easiest method to manage the main?

Colorectal cancer metastatic towards the liver is a superb model for implementing advances in multidisciplinary choose to get patients to surgery, that provides them the very best opportunity for lengthy-term survival, or perhaps a possible cure. Viable numerous studies to review these interventions and see which people are the best candidates are essential.


  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA-Cancer J Clin. 201262(1):10-29.
  2. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg. 1999230(3):309-318 discussion 318-321.
  3. Abdalla EK, Adam R, Bilchik AJ, et al. Improving resectability of hepatic colorectal metastases: Expert consensus statement. Ann Surg Oncol. 200613(10):1271-1280.
  4. Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J of Surg. 199519(1):59-71.
  5. Scheele J, Altendorf-Hofmann A. Surgical procedure of liver metastases. In: Blumgart LH, Fong Y, editors. Surgery from the Liver and Biliary Tract. 3rd erectile dysfunction. London: WB Saunders 2000: 1475-1502.
  6. Gertsch P. A historic perspective on colorectal liver metastases and peritoneal carcinomatosis: Similar results, different treatments. Surg Oncol Clin N Am. 200312(3):531-541.
  7. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil without or with oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 200018(16):2938-2947.
  8. Tournigand C, Andre T, Achille E, et al. FOLFIRI adopted by FOLFOX6 or even the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol. 200422(2):229-237.
  9. Adam R, Delvart V, Pascal G, et al. Save surgery for unresectable colorectal liver metastases downstaged by chemotherapy: One to calculate lengthy-term survival. Ann Surg. 2004240(4):644-657.
  10. Ye LC, Liu TS, Ren L, et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol. 201331(16):1931-1938.
  11. Kemeny N. Management of metastatic cancer of the colon: “The occasions they’re a-altering.” J Clin Oncol. 201331(16):1913-1916.
  12. Brouquet A, Abdalla EK, Kopetz S, et al. High rate of survival after two-stage resection of advanced colorectal liver metastases: Response-based selection and finish resection define outcome. J Clin Oncol. 201129(8):1083-1090.
  13. Resourse:

    Chemotherapy to Reduce Size of Liver Metastases for Surgical Resection – Top Liver Cancer Surgeon